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Abstract
Objective: Familial dysalbuminaemic hyperthyroxinaemia (FDH), most commonly due to an Arginine to Histidine 
mutation at residue 218 (R218H) in the albumin gene, causes artefactual elevation of free thyroid hormones in 
euthyroid individuals. We have evaluated the susceptibility of most current free thyroid hormone immunoassay 
methods used in the United Kingdom, Europe and Far East to interference by R218H FDH.
Methods: Different, one- and two-step immunoassay methods were tested, measuring free T4 (FT4) and free T3 (FT3) in 
37 individuals with genetically proven R218H FDH.
Results: With the exception of Ortho VITROS, FT4 measurements were raised in all assays, with greatest to 
lowest susceptibility to interference being Beckman ACCESS > Roche ELECSYS > FUJIREBIO Lumipulse > Siemens 
CENTAUR > Abbott ARCHITECT > Perkin-Elmer DELFIA. Five different assays recorded high FT3 levels, with the Siemens 
CENTAUR method measuring high FT3 values in up to 30% of cases. However, depending on the assay method, FT4 
measurements were unexpectedly normal in some, genetically confirmed, affected relatives of index FDH cases.
Conclusions: All FT4 immunoassays evaluated are prone to interference by R218H FDH, with their varying susceptibility 
not being related to assay architecture but likely due to differing assay conditions or buffer composition. Added 
susceptibility of many FT3 assays to measurement interference, resulting in high FT4 and FT3 with non-suppressed 
TSH levels, raises the possibility of R218H FDH being misdiagnosed as resistance to thyroid hormone beta or TSH-
secreting pituitary tumour, potentially leading to unnecessary investigation and inappropriate treatment.
Introduction
Familial dysalbuminaemic hyperthyroxinaemia, a 
dominantly inherited condition due to mutant circulating 
albumin with altered binding affinity for thyroid hormones 
(TH), is a recognized cause of artefactual elevation in free 
TH measurements in euthyroid individuals. Following 
its recognition as a biochemical entity (1, 2), two groups 
described the molecular basis of FDH, identifying a 
heterozygous mutation in the albumin gene, changing 
arginine at codon 218 in the protein to histidine (R218H) (3, 
4). The R218H albumin variant is the commonest form of 
FDH, with a reported prevalence of 1:10 000 in Caucasians 
(5), but may occur at a frequency of 1 in 100 in Hispanics (6).
In R218H FDH, total thyroxine (T4) levels are 
characteristically two- to three-fold elevated (3) , with 
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normal or mildly raised total triiodothyronine (T3) 
concentrations (7), reflecting a ten-fold higher T4 binding 
affinity (3) and five-fold higher T3 binding affinity of 
mutant albumin (8). Most clinical laboratories measure 
free thyroid hormones using automated immunometric 
assays, recording artefactually high FT4 measurements 
in this disorder (9, 10). One-step competitive assays are 
based on the principle that both endogenous free T4 and 
labelled T4 analogue (assay tracer) compete for binding 
to an immobilized T4-specific antibody, with measured 
FT4 concentrations being inversely proportional to the 
amount of captured labelled tracer. However, in FDH, 
enhanced interaction of the labelled T4 analogue with 
mutant albumin decreases its availability to compete 
with free T4 for capture antibody binding sites, resulting 
in spuriously high FT4 measurements (9). In contrast, in 
two-step assays, the labelled T4 analogue tracer is only 
introduced after an initial step in which the capture 
antibody and endogenous free T4 have been allowed to 
equilibrate, followed by a wash step which removes the 
interfering mutant albumin, purportedly eliminating 
susceptibility to assay interference. Circulating FT4 
measured by ‘gold standard’ assays such as equilibrium or 
symmetric dialysis or ultrafiltration would typically but 
not invariably (11) yield normal results, but these methods 
are labour intensive, time consuming and expensive.
The susceptibility of current FT4 and FT3 immunoassay 
methods to interference by FDH is unknown. Here, 
in an unselected cohort of individuals with differing 
normal hypothalamic-pituitary-thyroid axis setpoints, all 
harbouring the common R218H albumin variant causing 
FDH, we have measured FT4 and FT3 levels using most 
immunoassay methods currently in use in the United 
Kingdom, Europe and Far East.
Subjects and methods
FDH cohort
Serum samples from thirty-seven different, unselected 
cases of FDH, all harbouring an arginine to histidine 
mutation at codon 218 (R218H) in the albumin gene, 
were analysed. Individuals with abnormal serum 
TSH concentrations, suggesting coexistent thyroid 
dysfunction, were excluded. Investigations were either 
clinically indicated or undertaken as part of a protocol 
approved by our Research Ethics Committee (LREC 
98/154) with prior informed consent of participants.
Free and total thyroid hormone measurements
FT4 and FT3 measurements were undertaken as specified 
by manufacturers as follows: One-step immunoassay 
methods used: ADVIA CENTAUR XP®: Siemens Medical 
Solutions Diagnostics (reference range (RR) for FT4: 
10.0–19.8 pmol/L and FT3: 3.5–6.5 pmol/L); ELECSYS 
E170: Roche Diagnostics (RR for FT4: 12.0–22.0 pmol/L 
and FT3: 3.1–6.8 pmol/L) and VITROS Eci: Ortho Clinical 
Diagnostics (RR for FT4: 8.9–20.3 pmol/L and FT3: 4.1–7.9 
pmol/L). LUMIPULSE: Fujirebio (RR for FT4: 13.5–24.0 
pmol/L and FT3: 2.7–6.7 pmol/L). Two-step immunoassay 
methods used: Wallac DELFIA: Perkin Elmer (RR for FT4: 
9.0–20 pmol/L and FT3: 3.5–7.5 pmol/L); ARCHITECT 
c800: Abbott Ltd Diagnostics (RR for FT4: 8.0–21.0 pmol/L 
and FT3: 3.8–6.0 pmol/L) and ACCESS 2: Beckman Coulter. 
(RR for FT4: 6.3–14.0 pmol/L). FT4 measurements by 
three methods (Ortho VITROS Ec1, Fujirebio LUMIPULSE, 
Roche ELECSYS E170) were repeated in assay buffer 
supplemented with 2.5 mM sodium chloride.
Provenance of assays in National External Quality 
Assurance Scheme
The UK National External Quality Assurance Scheme 
(NEQAS) is a programme in which participating 
laboratories assess consistency and analytical bias of 
their local assay methods by periodically undertaking 
biochemical measurements in a panel of reference samples. 
To assess the range of free thyroid hormone immunoassay 
methods used in the United Kingdom, we quantified the 
provenance of FT4 and FT3 measurement methods used 
by different centres participating in the Quality Assurance 
Scheme for Thyroid Hormones.
Statistical analysis
For each assay method, measured mean FT4 and FT3 
concentrations were compared to the mean of the 
manufacturer’s or centre’s reference range and the 
differences between these means were analysed using 
a one sample t-test, with a P value of <0.05 denoting 
statistical significance.
Results
With the exception of Ortho VITROS, raised FT4 values were 
recorded in 43% to 100% of FDH cases, depending on the 
immunoassay method (Table 1). FT4 measurements were 
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all above the upper limit of normal with a two-step assay 
(Beckman: ACCESS); conversely, in a one-step method 
(Ortho: VITROS), normal or even underestimated, low FT4 
values were recorded (Fig. 1A). Mean measured vs mean 
of reference range FT4 values were significantly different 
for all assays, but some two-step methods (Perkin-Elmer: 
DELFIA; Abbott: ARCHITECT) recorded values closer to the 
reference range mean than one-step methods (Siemens: 
CENTAUR; Roche: ELECSYS) (Supplementary Fig. 1A, 
see section on supplementary materials given at the end 
of this article). The rank order of deviation in measured 
vs reference FT4 values with different assay methods 
(greatest to lowest) was Beckman: ACCESS > Roche: 
ELECSYS > Fujirebio: LUMIPULSE > Siemens: CENTAUR > 
Abbott: ARCHITECT > Perkin-Elmer: DELFIA. The Ortho 
VITROS method recorded lower mean FT4 values than its 
assay reference mean (Supplementary Fig. 1A). Increasing 
chloride concentration of assay buffer raised FT4 values 
measured by the Ortho VITROS method markedly, but had 
no effect on FT4 values measured by the Roche ELECSYS 
or Fujirebio LUMIPULSE methods (Supplementary Fig. 2).
Free T3 measurements were raised (Fig. 1B), but to a 
lesser degree than FT4, with high values being recorded 
in 11% to 30% of FDH cases using five different assay 
methods (Table 1). Differences between measured and 
reference range mean Free T3 values were smaller, with 
their rank order (greatest to lowest) being: Siemens 
CENTAUR > Fujirebio LUMIPULSE > Perkin-Elmer 
DELFIA > Roche ELECSYS > Abbott ARCHITECT, with the 
Ortho VITROS method recording mean FT3 values below 
its assay reference mean (Supplementary Fig. 1B).
We measured FT4 levels in eight individuals with 
genetically proven R218H FDH from four unrelated 
families using different assay methods. Unexpectedly, 
although the index FDH patient from a family exhibited 
raised FT4 levels, many measurement methods (e.g. Perkin-
Elmer DELFIA, Abbott ARCHITECT, Siemens CENTAUR) 
recorded normal FT4 levels in their relatives also known 
to be affected by this condition (Supplementary Fig. 3).
Discussion
Using a cohort of unselected, genetically confirmed, cases 
of familial dysalbuminaemic hyperthyroxinaemia due 
to the commonest causal albumin variant (R218H) in 
Caucasian populations, we have systematically evaluated 
susceptibility to assay interference of most free thyroid 
hormone measurement methods currently used in the 
United Kingdom, Europe and Far East. Both one-step 
(e.g. Roche ELECSYS, Siemens CENTAUR) and two-step 
(e.g. Beckman ACCESS) FT4 measurement methods are 
markedly susceptible to interference. In addition, we find 
that one-step (e.g. Siemens CENTAUR, Roche ELECSYS) 
and two-step (e.g. Abbott ARCHITECT, Perkin-Elmer 
DELFIA) FT3 measurement methods are also susceptible 
to interference, recording high FT3 values in up to 30% 
of cases. Measurement methods most susceptible to 
interference (FT4: Roche ELECSYS, Siemens CENTAUR, 
Beckman ACCESS; FT3: Siemens CENTAUR, Roche 
ELECSYS, Abbott ARCHITECT) are also the most frequent 
types of assay participating in the UK national quality 
assurance scheme (Fig. 1C and D) or are an assay method 
(Fujirebio LUMIPULSE) that is widely used in the Far East, 
suggesting that the potential for recording artefactually 
elevated free thyroid hormone levels and consequent 
misdiagnosis is of immense clinical relevance.
The varying susceptibility of different measurement 
methods to interference by FDH does suggest that differing 
assay methodologies account for this, but our results 
indicate that one-step vs two-step assay architecture is 
unlikely to be the major determinant. Thus, a two-step 
FT4 assay (Beckman ACCESS) recorded highest FT4 values, 
whereas a one-step FT4 method (Ortho VITROS) recorded 
normal or even slightly low FT4 values. Indeed, in our 
experience, discordance between low FT4 measurements 
in Ortho VITROS and high FT4 values using other 
methods is highly suggestive of FDH. Our findings accord 
with previous observations showing that some two-step 
assays yield spuriously high FT4 values in FDH (10). 
Manufacturers have sought to minimize susceptibility to 
measurement interference by altering the composition of 
incubation buffer to inhibit binding of T4 or labelled T4 
analogues (used in one-step but also two-step assays) to 
albumin. Increasing the concentration of chloride ions 
in assay buffer has been shown to increase FT4 values 
even when measured using ‘gold standard’ methods such 
as equilibrium dialysis (12) or symmetric dialysis (13), 
with this effect being much more pronounced with FDH 
Table 1 Percentage of Free T4 and Free T3 values above the upper limit of reference range using different assay methods.
Assay method
Delfia Architect Access Centaur Elecsys Vitros Lumipulse
Free T4 (%) 46 43 100 84 92 0 92
Free T3 (%) 14 14 – 30 19 0 11
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Free T4 (panel A) or Free T3 (panel B) measurements in FDH individuals using different assay methods. Closed circles denote 
individual data, with horizontal lines corresponding to the mean of measured values. The dotted line and shaded grey box 
represent the mean and reference range of each assay. (C and D) Histograms showing the number of different FT4 (panel C) or FT3 
(panel D) measurement methods recorded by centres returning data in the UK National External Quality Assurance (QA) Scheme.
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vs normalbuminaemic serum samples. Thus, as others 
have noted previously, the FT4 assay method we found 
most susceptible to interference (Beckman ACCESS) uses 
incubation buffer with a high chloride content, whereas 
the method least susceptible to positive interference 
(Ortho VITROS) makes measurements using chloride-
free medium (13). Supporting this notion, we found that 
increasing chloride concentration of assay buffer affected 
FT4 measured by Ortho VITROS markedly. However, 
increased chloride had minimal effect on FT4 measured 
by Roche ELECSYS or Fujirebio LUMIPULSE, suggesting 
that other proprietary constituents of assay buffers, 
whose identity is difficult to ascertain, are responsible 
for assay interference in different measurement methods. 
Moreover, we have found that the current Siemens 
CENTAUR FT4 measurement method is much more 
prone to interference by FDH than the assay version we 
evaluated in 2009 (14), indicating that change in assay 
design by manufacturers is a further variable influencing 
susceptibility to interference.
Studies in our large R218H FDH cohort indicate that 
current FT3 measurement methods are also susceptible to 
interference, albeit to a lesser degree, possibly also due to 
the lower T3 binding affinity of mutant albumin. Such 
artefactual FT3 elevation, generating a pattern of thyroid 
function tests (raised FT4 and FT3, non-suppressed TSH) 
which mimics disorders such as Resistance to Thyroid 
Hormone beta or pituitary, TSH-secreting tumour, is 
clinically significant because it may provoke unwarranted 
investigation (e.g. MRI scan, dynamic endocrine testing) 
or treatment (e.g. pituitary surgery, triiodothyroacetic acid 
or somatostatin analogue therapy), with attendant cost 
or morbidity (15). Conversely, low, recorded FT4 levels, 
measured by the Ortho VITROS method, could lead to a 
misdiagnosis of central hypothyroidism.
Substantial interindividual differences in free 
thyroid hormone levels suggest differing setpoints of the 
hypothalamic-pituitary-thyroid axis in healthy subjects, 
with a complex, underlying polygenic basis (16). We 
suggest that such interindividual variation in pituitary-
thyroid axis setpoint might also account for normal FT4 
values being recorded in some FDH family members even 
though the index case in the kindred was identified on the 
basis of raised FT4 using the same measurement method. 
Accordingly, we suggest that definitive diagnostic methods 
(e.g. radiolabelled T4 binding to serum proteins, albumin 
gene sequencing) rather than biochemical screening using 
free thyroid hormone measurements should be used to 
ascertain the status of relatives in families with FDH.
The relatively high prevalence and familial nature 
of FDH, together with susceptibility of both commonly 
used current FT4 and FT3 immunoassay methods to 
interference from this condition, suggests that this entity 
is not only a significant cause of discordant thyroid 
function but potentially responsible for substantial 
misdiagnosis, unnecessary investigation and inappropriate 
management.
Supplementary materials
This is linked to the online version of the paper at https://doi.org/10.1530/
EJE-19-1021.
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